1Denny L, Kuhn L, Pollack A, et al. Direct visual inspection for cervical cancer screening: an analysis of factors influencing test performance. Cancer, 2002,94(6): 1699-1707.
2Patnick J. Cevical cancer control in Europe. CME J Gynecol Oncol,2000,5:8-11.
3Harper DM, Noll WW, Belloni DR, et al. Randomized clinical trial of PCB--determined human papillomavirus detection methods: selfsampling versus clinician-directed-biologic concordance and women's preferences. Am J Obstet Gynecol, 2002,186(3):365-373.
4Mandelblatt JS, Lawrence WF, Womack SM, et al. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA,2002, 287(18):2372-2381.
5Heley S. Human papillomavims: beware the infection you can't see.Aust Faro Physician, 2003,32(5):311-315.
6Berhard Kleter, Leen-Jan van Doom,Jan ter Schegget,et al. Novel Short Fragment PCR Assay for Highly Sensitive Broad-Spectrum Detection of Anogenital Human Papillomaviruses. Am J Pathol,1998,153(6):1731-1739.
7van Den Brule AJ, Pol R, Fransen-Daalmeijer N, et al. GPS+/6+ PCR followed by Reverse Line Blot Analysis Enables Rapid and High-Throughput Identification of Human Papillomavirus Genotypes. J Clin Microbiol,2002,40(3):779-787.
8Pretofius RG, Peterson P, Novak S, et al. Comparison of two signalamplification DNA tests for high-risk HPV as an aid to colposcopy. J Reprod Med, 2002,47(4):290-296.
9Jason DW, Thomas JH. Human papillomavirus: Emerging Trends in Detection and Management. Current Women's Health Reports, 2002,2:259-265.
10Denise Zielinski G, Snijders PJ, Rozendaal L, et al. High-risk HPV testing in women with borderline and mild dyskaryosis: long-term follow-up data and clinical relevance. J Pathol,2001,195(3):300-306.
